Amylyx Pharmaceuticals Inc (AMLX)vsTeva Pharma Industries Ltd ADR (TEVA)
AMLX
Amylyx Pharmaceuticals Inc
$16.28
-6.92%
HEALTHCARE · Cap: $1.69B
TEVA
Teva Pharma Industries Ltd ADR
$34.22
+3.04%
HEALTHCARE · Cap: $40.32B
Smart Verdict
WallStSmart Research — data-driven comparison
Teva Pharma Industries Ltd ADR generates -2608972% more annual revenue ($17.35B vs $-665,000). TEVA leads profitability with a 9.0% profit margin vs 0.0%. TEVA earns a higher WallStSmart Score of 66/100 (B-).
AMLX
Avoid31
out of 100
Grade: F
TEVA
Strong Buy66
out of 100
Grade: B-
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Earnings expanding 72.2% YoY
Growing faster than its price suggests
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
Moderate valuation
2.3% revenue growth
Negative free cash flow — burning cash
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : AMLX
The strongest argument for AMLX centers on Debt/Equity, Altman Z-Score.
Bull Case : TEVA
The strongest argument for TEVA centers on EPS Growth, PEG Ratio. PEG of 0.85 suggests the stock is reasonably priced for its growth.
Bear Case : AMLX
The primary concerns for AMLX are EPS Growth, Market Cap, Profit Margin.
Bear Case : TEVA
The primary concerns for TEVA are P/E Ratio, Revenue Growth, Free Cash Flow. Debt-to-equity of 2.05 is elevated, increasing financial risk.
Key Dynamics to Monitor
TEVA carries more volatility with a beta of 0.85 — expect wider price swings.
TEVA is growing revenue faster at 2.3% — sustainability is the question.
AMLX generates stronger free cash flow (-37M), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.
Bottom Line
TEVA scores higher overall (66/100 vs 31/100). Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Amylyx Pharmaceuticals Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Amylyx Pharmaceuticals Inc (AMLX) is a pioneering biopharmaceutical company dedicated to creating transformative therapies for neurodegenerative diseases, with a primary focus on amyotrophic lateral sclerosis (ALS). The company’s lead product candidate, AMX0035, features an innovative neuroprotective mechanism that has demonstrated promising results in enhancing patient outcomes. Backed by a strong clinical pipeline and a team of specialists in neurology, Amylyx is strategically positioned to address critical unmet medical needs, presenting a compelling investment opportunity for institutional investors interested in cutting-edge solutions for challenging neurological disorders.
Teva Pharma Industries Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?